NasdaqGS - Nasdaq Real Time Price USD

Rigel Pharmaceuticals, Inc. (RIGL)

Compare
16.54 +0.10 (+0.61%)
As of 11:05:23 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
157,474.00
116,882.00
120,242.00
149,236.00
108,621.00
Cost of Revenue
16,648.00
7,110.00
1,749.00
1,083.00
895.00
Gross Profit
140,826.00
109,772.00
118,493.00
148,153.00
107,726.00
Operating Expense
131,323.00
130,263.00
172,723.00
157,128.00
136,699.00
Operating Income
9,503.00
-20,491.00
-54,230.00
-8,975.00
-28,973.00
Net Non Operating Interest Income Expense
-5,622.00
-4,600.00
-3,023.00
-4,813.00
-771.00
Other Income Expense
--
--
-1,320.00
-3,521.00
--
Pretax Income
3,881.00
-25,091.00
-58,573.00
-17,309.00
-29,744.00
Tax Provision
--
--
--
605.00
--
Net Income Common Stockholders
3,881.00
-25,091.00
-58,573.00
-17,914.00
-29,744.00
Diluted NI Available to Com Stockholders
3,881.00
-25,091.00
-58,573.00
-17,914.00
-29,744.00
Basic EPS
0.27
-1.40
-3.40
-1.10
-1.80
Diluted EPS
0.27
-1.40
-3.40
-1.10
-1.80
Basic Average Shares
17,526.95
17,401.70
17,240.60
17,049.20
16,875.40
Diluted Average Shares
17,559.20
17,401.70
17,240.60
17,049.20
16,875.40
Total Operating Income as Reported
9,503.00
-20,491.00
-55,550.00
-12,496.00
-28,973.00
Total Expenses
147,971.00
137,373.00
174,472.00
158,211.00
137,594.00
Net Income from Continuing & Discontinued Operation
3,881.00
-25,091.00
-58,573.00
-17,914.00
-29,744.00
Normalized Income
3,881.00
-25,091.00
-57,254.32
-14,519.76
-29,744.00
Interest Income
2,248.00
2,272.00
684.00
47.00
582.00
Interest Expense
7,870.00
6,872.00
3,707.00
4,860.00
1,353.00
Net Interest Income
-5,622.00
-4,600.00
-3,023.00
-4,813.00
-771.00
EBIT
11,751.00
-18,219.00
-54,866.00
-12,449.00
-28,391.00
EBITDA
13,668.00
-16,981.00
-53,868.00
-11,287.00
-27,685.00
Reconciled Cost of Revenue
16,648.00
7,110.00
1,749.00
1,083.00
895.00
Reconciled Depreciation
1,917.00
1,238.00
998.00
1,162.00
706.00
Net Income from Continuing Operation Net Minority Interest
3,881.00
-25,091.00
-58,573.00
-17,914.00
-29,744.00
Total Unusual Items Excluding Goodwill
--
--
-1,320.00
-3,521.00
--
Total Unusual Items
--
--
-1,320.00
-3,521.00
--
Normalized EBITDA
13,668.00
-16,981.00
-52,548.00
-7,766.00
-27,685.00
Tax Rate for Calcs
0.00
--
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-1.32
-126.76
--
12/31/2020 - 11/29/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IMCR Immunocore Holdings plc
29.49
+2.88%
 
KPTI Karyopharm Therapeutics Inc.
0.5996
+0.77%
 
CRIS Curis, Inc.
3.2500
+2.52%
 
LXRX Lexicon Pharmaceuticals, Inc.
0.7153
-5.62%
 
GLUE Monte Rosa Therapeutics, Inc.
7.20
+2.06%
 
VNDA Vanda Pharmaceuticals Inc.
4.8300
0.00%
 
ETNB 89bio, Inc.
8.00
+0.76%
 
PBYI Puma Biotechnology, Inc.
3.0811
+2.02%
 
CDTX Cidara Therapeutics, Inc.
23.13
-1.30%
 
VYGR Voyager Therapeutics, Inc.
5.82
+0.69%